Cost-Effectiveness of Denosumab Versus Zoledronic Acid in the Management of Skeletal Metastases Seco...
Cost-Effectiveness of Denosumab Versus Zoledronic Acid in the Management of Skeletal Metastases Secondary to Breast Cancer
About this item
Full title
Author / Creator
Publisher
Bridgewater, NJ: Elsevier Inc
Journal title
Language
English
Formats
Publication information
Publisher
Bridgewater, NJ: Elsevier Inc
Subjects
More information
Scope and Contents
Contents
AbstractBackgroundDenosumab has been approved in the United States for the prevention of skeletal-related events (SREs) in metastatic breast cancer. In a Phase III trial in patients with bone-metastatic breast cancer (N = 2033), denosumab was associated with a significantly delayed time to first SRE (by 18%; P < 0.001 noninferiority; P = 0.01 super...
Alternative Titles
Full title
Cost-Effectiveness of Denosumab Versus Zoledronic Acid in the Management of Skeletal Metastases Secondary to Breast Cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1020511173
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1020511173
Other Identifiers
ISSN
0149-2918
E-ISSN
1879-114X
DOI
10.1016/j.clinthera.2012.04.008
